Playlists - Cancer Therapy Startups

Cancer therapy

The Patient Story

Cancer Patient Lab

“My vision is that every person, even the healthy ones, are getting fully personalized, anti-cancer vaccines. The reason why I believe this is so relevant is because we need to have immune responses before we get sick. I built a prophylactic cancer vaccine for my husband, Dirk, and myself. I tested the peptides. I noticed that I already have T-cell responses. I see for many patients that they do not have a pre-existing T-cell response against their driver mutations, so that there must be a time where the immune system is failing, or maybe some patients do not build up these relevant immune responses. I believe that everyone should have access to a fully personalized anti-cancer vaccine during their lifetime.” – Saskia Biskup

Many cancers are aggressive and have few good treatment options, like pancreatic cancer and glioblastoma, which is an aggressive brain cancer. Getting a diagnosis of one of these cancers is devastating. They are often diagnosed very late, and are usually fatal. There are few good treatment options. Patients who are diagnosed with these cancers are confronted with difficult decisions that must be made urgently. Immunotherapies provide lots of promise. But for glioblastoma, brain treatments must pass the blood-brain barrier. Immunotherapies have been very successful in blood cancers, but less so in solid tumors. Personalized cancer vaccines have promise across many cancers, and much research is being done.

Dr. Saskia Biskup, MD, PhD, co-founder and managing director at the Center for Genomics and Transcriptomics (CeGaT GmbH) in Tuebingen, Germany, is uniquely qualified to lead a discussion on the potential of personalized cancer vaccines, especially in brain cancer. She received her medical degree and her PhD at the University of Wuerzburg, Germany. She started her professional training in human genetics at the Technical University in Munich, Germany. She co-founded CeGaT with her husband, Dirk, in 2009. CeGaT is a leader in genetics testing. Dirk and Saskia founded Cecava with the aim to launch a clinical trial for a personalized cancer vaccine for glioblastoma. Other clinical trials will follow. They are notable for connecting test results to your personalized care context.

The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health.

The Potential of Personalized Cancer Vaccines - Dr. Saskia Biskup, MD

“I am convinced that he larger steps will come from the multiomics approach. We frequently see that genes are not everything. You need the transcriptome, the proteome, the spatial information, metabolomic information, metabolites, and the microbiome." - Dr. Saskia Biskup, MD, PhD

Many cancers are aggressive and have few good treatment options, like pancreatic cancer and glioblastoma, which is an aggressive brain cancer. Getting a diagnosis of one of these cancers is devastating. They are often diagnosed very late, and are usually fatal. There are few good treatment options. Patients who are diagnosed with these cancers are confronted with difficult decisions that must be made urgently. Immunotherapies provide lots of promise. But for glioblastoma, brain treatments must pass the blood-brain barrier. Immunotherapies have been very successful in blood cancers, but less so in solid tumors. Personalized cancer vaccines have promise across many cancers, and much research is being done.

Dr. Saskia Biskup, MD, PhD, co-founder and managing director at the Center for Genomics and Transcriptomics (CeGaT GmbH) in Tuebingen, Germany, is uniquely qualified to lead a discussion on the potential of personalized cancer vaccines, especially in brain cancer. She received her medical degree and her PhD at the University of Wuerzburg, Germany. She started her professional training in human genetics at the Technical University in Munich, Germany. She co-founded CeGaT with her husband, Dirk, in 2009. CeGaT is a leader in genetics testing. Dirk and Saskia founded Cecava with the aim to launch a clinical trial for a personalized cancer vaccine for glioblastoma. Other clinical trials will follow. They are notable for connecting test results to your personalized care context.

The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health.

"The Potential of Personalized Cancer Vaccines" Saskia Biskup, MD

“I would rather combine strategies than pretend that there's a magic bullet. We have one platform technology, which is the neoantigen platform, but it can be easily combined." - Dr. Saskia Biskup, MD, PhD

Many cancers are aggressive and have few good treatment options, like pancreatic cancer and glioblastoma, which is an aggressive brain cancer. Getting a diagnosis of one of these cancers is devastating. They are often diagnosed very late, and are usually fatal. There are few good treatment options. Patients who are diagnosed with these cancers are confronted with difficult decisions that must be made urgently. Immunotherapies provide lots of promise. But for glioblastoma, brain treatments must pass the blood-brain barrier. Immunotherapies have been very successful in blood cancers, but less so in solid tumors. Personalized cancer vaccines have promise across many cancers, and much research is being done.

Dr. Saskia Biskup, MD, PhD, co-founder and managing director at the Center for Genomics and Transcriptomics (CeGaT GmbH) in Tuebingen, Germany, is uniquely qualified to lead a discussion on the potential of personalized cancer vaccines, especially in brain cancer. She received her medical degree and her PhD at the University of Wuerzburg, Germany. She started her professional training in human genetics at the Technical University in Munich, Germany. She co-founded CeGaT with her husband, Dirk, in 2009. CeGaT is a leader in genetics testing. Dirk and Saskia founded Cecava with the aim to launch a clinical trial for a personalized cancer vaccine for glioblastoma. Other clinical trials will follow. They are notable for connecting test results to your personalized care context.

The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health.

"The Potential of Personalized Cancer Vaccines" - Dr. Saskia Biskup, MD, PhD

Roger Royse - FDA Advisory Committe